ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Abstracts tagged "methotrexate (MTX) and DMARDs"

  • Abstract Number: 2400 • ACR/ARP Annual Meeting 2019

    The Effect of Co-medication with Methotrexate and Other Conventional Synthetic Disease Modifying Anti-rheumatic Drugs on First Tumor Necrosis Inhibitor Drug Survival in Patients with Rheumatoid Arthritis: Results Form a Nationwide Registry

    Herman Mann1, Lucie Nekvindová 2, Jakub Závada 3, Zlatuše Křístková 2, Pavel Horák 4, Jiří Vencovský 1 and Karel Pavelka 1, 1Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 2Institute of Biostatistics and Analyses Ltd., spinoff company of Masaryk University, Brno, Czech Republic, 3Institute of Rheumatology, Prague, Prague, Czech Republic, 4Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) should be used for the treatment of rheumatoid arthritis (RA) in combination with conventional synthetic disease modifying anti‑rheumatic drugs…

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology